Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0476089 (endometrial cancer)
 11,379 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Ovarian secretion of testosterone and androstenedione is increased in postmenopausal women with endometrial cancer, and insulin stimulates ovarian stromal androgen synthesis in vitro. We undertook this study to investigate whether women with endometrial cancer have increased serum immunoreactive insulin levels. Ten postmenopausal women with endometrial carcinoma and 10 postmenopausal women without cancer who matched the cancer patients in age, years since menopause, and percentage of ideal body weight were studied. The women with endometrial cancer had significantly higher fasting serum insulin levels than the normal women [mean, 187 +/- 26 (+/- SE) vs. 55 +/- 11 pmol/L; P less than 0.01]. The cancer patients had significantly higher insulin responses after glucose administration than normal women (sum of 1, 2, and 3 h postglucose values, 5545 +/- 1526 vs. 1444 +/- 156 pmol/L; P less than 0.02), even though their glucose responses were similar. Nests of luteinized cells, which were positive for testosterone by immunoperoxidase staining, were found in the ovarian stroma of 8 of the women with endometrial cancer, but in only 1 of those without cancer (P less than 0.01). Specific high affinity insulin receptors were demonstrable in the stroma of the postmenopausal ovaries. These results suggest that the frequency of stromal luteinization is increased in women with endometrial cancer and that insulin may play a role in the pathogenesis of this luteinization.
 ...
PMID:Hyperinsulinemia and stromal luteinization of the ovaries in postmenopausal women with endometrial cancer. 328 50

Plasma estrone (E1), 17 beta-estradiol (E2), delta 4-androstenedione (delta 4-A) and testosterone (T) levels in the peripheral vein were measured in 28 postmenopausal women with endometrial cancer and 19 control subjects without cancer matched to the cancer patients for age and weight. In the cancer patients, the mean +/- SD plasma E1, E2, delta 4-A and T levels were 53.0 +/- 29.0pg/ml, 31.3 +/- 28.9pg/ml, 1.92 +/- 0.96ng/ml and 0.71 +/- 0.24ng/ml, respectively. In the controls, the mean +/- SD plasma E1, E2, delta 4-A and T levels were 51.2 +/- 27.5pg/ml, 22.4 +/- 10.1 pg/ml, 1.70 +/- 0.6ng/ml and 0.84 +/- 0.24ng/ml, respectively. Similar concentrations were found in the control subjects. The correlation of each steroids with the percentage of ideal weight was examined. The percentage of ideal weight showed no correlation with E1, E2, delta 4-A and T in either group. Insulin response during glucose administration in the cancer patients was examined, and showed no correlation with each steroids. It was concluded that there is no differences between E1, E2, delta 4-A and T levels in cancer patients and control subjects matched to the cancer patients for age and weight. No correlation of insulin with ovarian steroid production was seen in the cancer patients.
 ...
PMID:[Plasma concentration of estrogens and androgens in postmenopausal women with or without endometrial cancer]. 329 74

The vaginal cytology of 507 postmenopausal women was followed prospectively for ten years. Of the subjects, the 207 with cytolytic or karyopyknotic vaginal smears constituted the study group and the 300 with atrophic smears (indicating an absence of estrogenic activity) constituted the control group at the beginning of the follow-up. A woman whose initial smear was cytolytic usually had a cytolytic smear ten years later, which implies that high postmenopausal estrogenic activity is constitutional. Both at the beginning of the study and ten years later, the mean body weights were higher in the study group than in the control group. The mean karyopyknotic index and the prevalence of cytolytic smears were significantly higher among women with impaired glucose tolerance than among subjects with a normal glucose tolerance test. During the follow-up period, 3.6% of the women in the study group and 0.7% of the women in the control group developed endometrial cancer (P less than .02). The incidence of 3.6% of endometrial cancer is significantly higher than the corresponding age-specific incidence (P less than .001). We conclude that obese and/or diabetic postmenopausal women with cytolytic or markedly karyopyknotic vaginal smears exhibit a high intrinsic estrogen activity and may thus be at risk for endometrial cancer.
 ...
PMID:Cytolysis and karyopyknosis in postmenopausal vaginal smears as markers of endometrial cancer, diabetes and obesity. Studies based on a ten-year follow-up. 346 99

This review briefly outlines the pharmacology of natural and synthetic estrogens, and synthetic progestins, and summarizes their beneficial and adverse effects for contraceptive and menopausal therapy. Currently, oral contraceptives contain 30-50 mc synthetic estrogen, and 1-5 mg nor-progestin; menopausal therapy may be either 0.625-1.25 mg natural estrogen or estrogen plus 10 mg medroxyprogesterone acetate daily if the woman has her uterus. The biologic effects of estrogens are : decrease in lipoproteins, increased blood coagulation factors, increased blood pressure, decreased glucose tolerance. Progestins increase blood lipids and increase insulin and glucose. Oral contraceptives increase the risk of cardiovascular disease, particularly in smokers and in women over 35, in proportion to dose. These studies should be recapitulated in more detail with the newer low-dose pills. Orals have far more beneficial effects, besides providing an inexpensive, effective method contraception. The death rate of users of oral contraceptives is 3.7/100,000 (1.8 in nonsmokers and 6.5 in smokers), but the risk is 5.5 times higher in nonusers exposed to pregnancy and childbirth. The risk for users of barrier methods backed up by abortion is lower, but pills are cheaper and more acceptable. If woman did not take oral contraceptives, they would not be protected from cancer of the breast, ovary, endometrium, and ovarian and breast cysts. Menopausal therapy puts woman at increased risk of endometrial cancer only if the estrogen is taken alone, not if progestin is combined with the estrogen. There are no other adverse effects except decreased glucose tolerance and possible comprise of lipoproteins if a norprogestin of menopausal estrogens effectively treat hot flashes, depression, vaginal atrophy and bones loss.
 ...
PMID:The adverse effects of hormonal therapy. 351 31

16 patients with carcinoma of the endometrium were treated with 50-mg medroxyprogesterone im twice daily for 1 year and studied to determine what effect this high dose of progesterone had on carbohydrate metabolism and liver function. Oral glucose tolerance values (fasting and 2 hour) were significantly elevated (p less than .001) at 12 and 18 months. Conjugated bilirubin was significantly elevated (p less than .01) at 18 months, aspartate aminotransferase was significantly elevated (p less than .001) at 12 and 18 months. Insulin values were raised transiently at 3 months. It is conluded that the changes in carbohydrate and liver function were small, appeared slowly, and included only a few pathologically elevated values; consequently the use of high-dose progestogen treatment for a 1-year period is considered safe.
 ...
PMID:Effects of high-dose medroxyprogesterone treatment given for endometrial carcinoma on carbohydrate metabolism and liver function. 485 52

Of 51 patients more than 2 years beyond the menopause, 34 had a diagnosis of endometrial carcinoma. Any with liver involvement were not included. 14 were found to have abnormal glucose metabolism. Each patient received an intravenous infusion of 8 mcc of bata-6, 7H-3 dissolved in 10 cc of 10% propylene glycol. 96 hour urine collections were obtained by an indwelling catheter. Values for the recovery of radioactivity associated with estrone, estradio, estriol, and estriol/estrone + estradiol expressed in percent of injected radioactivity are given. A wide range of values was obtained and great variations in ratios. Generally the results were similar to those obtained from studies on menstruating females. There was no significant difference between patients with or without endometrial carcinoma in terms of recovered radioactivity or of the estriol quotient. However, methoxgestrone, epiestriol, and the alpha-ketols which make up a significant portion of theurinary metabolites of estradiol 17 beta were not studied. Restudy of 6 patients with carcinoma produced constant patterns of metabolism. A significantly lower specific activity of estriol as compared to that of estrone was demonstrated in both groups of patients when estradiol 17 beta had been administered. However, this difference was less precursons of urinary estriol. Androstenedione may be one of these. Reasonable radiochemical purity of each final metabolite was verified by recrystallization to constant specific activity following the addition of nouradioactive estrone or estriol.
 ...
PMID:Estrogen metabolism in patients at high risk for endometrial carcinoma. I. Urinary metabolites of H3-estradiol in normal postmenopausal women and those with endometrial carcinoma. 536 Feb 44

This prospective study determines the presence of a consistent endocrine disturbance in patients with endometrial carcinoma. A major requirement of the study was an unbiased control group matched as to age, race, economic status, and primary reason for referral. All patients with untreated endometrial carcinoma or postmenopausal bleeding were studied and grouped into: 1) endometrial carcinoma (n=56), and 2) atrophic endometrium (n=83), or the "bleeding" controls. Average age of patients with carcinoma was 63.9 years and that of controls, 61.3 years. Factors studied were glucose metabolism, estrogenic activity, gonadotropin excretion, obesity, hypertension, time of climacteric, fertility, and menstrual history. By averaging deviations from ideal weight, cancer patients were found to be 13.1 pounds heavier than the control group (49.8 pounds vs. 36.7 for the controls). Analysis of fertility data showed that age at time of marriage in patients who were parous compared with those who were nulliparous was 20.1 and 26.8 years respectively for the carcinoma group, and 20.4 and 27.5 years for the bleeding controls. Of parous cancer patients, 6.3% used contraception vs. 13% of the controls. These data do not suggest that pregnancy prevention by late marriage or contraception plays a significant role in the later development of endometrial carcinoma. Hypertension, time of menopause, diabetes, estrogenic activity, and gonadotropin excretion did not exhibit significant effects in the development of carcinoma. The findings support those of Corscaden, Fertig, and Gusberg that obesity and infertility are statistical concomitants with endometrial carcinoma but contradict current belief that there is direct evidence of abnormal endocrine state (e.g., glucose metabolism, estrogen stimulation, or anterior pituitary activity).
 ...
PMID:Endocrine factors in endometrial carcinoma. A preliminary report. 601 48

Reduced estrogen content has significantly decreased the risks of oral contraceptive (OC) use. However, the systemic effects of OCs, but it is unclear if this change is physiologically significant. Estrogen-mediated inhibition of cortisol levels may contribute to the impairment of glucose tolerance by OCs. Women at high risk for diabetes, older than 35, obese, with family history of diabetes, or who have had glucose intolerance during previous pregnancies should either not take OCs or take pregestin-only pills. OCs raise plasma triglyceride levels 30-50 mg per dl in users of all ages. High density lipoprotein (HDL) cholesterol is also affected, and cholesterol and triglyceride levelshould be measured before and during OC use. The risk of hepatic adenoma rises with duration of OC use; however, most adenomas diagnosed before hemorrhage have regressed with discontinuation of the contraceptive regimen. The most significant adverse effects of OC use involve the arterial and venous vascular systems. OCs appear to raise the blood pressure in nearly all women. Change in systolic pressure is consistently greater than in diastolic, suggestingthat the primary hypertensive effect of OCs is on blood volume and cardiac output. Accumulated data indicate that if OCs are not used by women older than 35 or by women who smoke or who are hypertensive, then risk of subarachnoid hemorrhage or other cerebrovascular complication is very small. The relative risk of myocardial infarction in OC users has been from 0-6 times greater than in nonusers; this may depend on other confounding risk factors. Reduction in estrogen content of OCs decreases risk accordingly. The preponderance of evidence indicates that prolonged use of OCs does not increase risk of breast disease or ovarian and endometrial cancer, and, in fact, may protect users from malignant lesions by suppressing gonadotropins and ovulation.
 ...
PMID:Systemic effects of oral contraceptives. 608 41

The glycogen content and glycogen synthetase and glycogen phosphorylase levels were studied in tissues of endometrial carcinoma obtained from 30 patients (27 postmenopausal and three premenopausal) before and after administration of progestogen, and the values were compared with those obtained previously from normal endometrial tissue of premenopausal patients. After the patients had undergone an oral glucose tolerance test (OGTT), the progestogen Lyndiol (lynestrenol, 5.0 mg, and mestranol, 0.15 mg) was administered daily for seven days. In 15 cases of well differentiated carcinoma the glycogen content after the progestogen administration, accompanied by a corresponding increase in the glycogen synthetase enzyme levels, was significantly higher (P less than 0.005) than that in the initial tissue, whereas in the other 15 cases of less differentiated carcinoma no change was observed. This finding that hormonal stimulus in well differentiated carcinoma leads to a similar effect on glycogen metabolism as in normal endometrium of the proliferative phase of the menstrual cycle, supports the possibility of progestogen therapy for human endometrial cancer.
 ...
PMID:Hormone dependency of carcinoma of the human endometrium. Effect of progesterone on glycogen metabolism in the carcinoma tissue. 621 87

Seventeen women aged 55 to 76 years who had been treated for endometrial cancer by surgery or radiotherapy or a combination of both were given 300 mg of medroxyprogesterone acetate (MPA) daily by mouth. Before treatment and again during the 3rd week of treatment an oral glucose tolerance test (with measurement of serum insulin levels) and an ACTH-stimulation test were done. All blood glucose levels tended to be higher with MOA therapy and serum insulin levels were significantly increased 3 h after a glucose load. The rise of serum cortisol 30 min after ACTH-stimulation was significantly less with MPA therapy. Oral MPA thus appeared to have a glucocorticoid-like action.
 ...
PMID:The influence of high doses of oral medroxyprogesterone acetate on glucose tolerance, serum insulin levels and adrenal response to ACTH. A study of 17 patients under treatment for endometrial cancer. 625 52


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>